European Backing For AstraZeneca’s Olaparib Bolsters Barriers To Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe’s top medicines advisory panel, the CHMP, also recommended for approval Clinuvel’s Scenesse for severe intolerance to sunlight, Pfizer’s new combination menopausal symptom therapy Duavive, and Baxter’s new hemophilia B therapy Rixubis.
You may also be interested in...
Scenesse Approval Buoys Clinuvel As It Fights Retrophin
The Australian firm Clinuvel sees good prospects for its dermatology product Scenesse, but at the same time is fighting off unwanted acquisition advances from a corporate suitor.
Scenesse Approval Buoys Clinuvel As It Fights Retrophin
The Australian firm Clinuvel sees good prospects for its dermatology product Scenesse, but at the same time is fighting off unwanted acquisition advances from a corporate suitor.
Pfizer’s Duavee Approved For Hot Flashes, Osteoporosis Prevention
FDA cleared the single pill combining conjugated estrogens with bazedoxifene, a novel selective estrogen receptor modulator, for two indications but issued a “complete response” letter for use in vulvar and vaginal atrophy.